Changes in the PC compartment in patients with multiple myeloma, according to treatment group
| PC variable . | Treatment group . | P . | |
|---|---|---|---|
| ASCT (n = 47) . | Chemotherapy (n = 40) . | ||
| % MM-PCs | 0.04 (0-3.2) | 0.17 (0-3.7) | .01 |
| % N-PCs | 0.2 (0-0.16) | 0.12 (0-0.9) | .25 |
| % N-PCs/TPCs | 86 (0-100) | 35 (0-100) | .01 |
| No MRD (% of patients) | 36% | 15% | .04 |
| PC variable . | Treatment group . | P . | |
|---|---|---|---|
| ASCT (n = 47) . | Chemotherapy (n = 40) . | ||
| % MM-PCs | 0.04 (0-3.2) | 0.17 (0-3.7) | .01 |
| % N-PCs | 0.2 (0-0.16) | 0.12 (0-0.9) | .25 |
| % N-PCs/TPCs | 86 (0-100) | 35 (0-100) | .01 |
| No MRD (% of patients) | 36% | 15% | .04 |
Values are medians (range) unless otherwise indicated. The PC compartment was assessed 3 months after transplantation in the autologous stem cell transplantation (ASCT) group and after 12 cycles of conventional chemotherapy in the chemotherapy group.
% MM-PCs indicates percentage of myelomatous PCs among total bone marrow (BM) cells; % N-PCs, percentage of normal PCs cells among total BM cells; % N-PCs/TPCs, percentage of normal PCs among total purified/gated BMPCs; and No MRD, no minimal residual disease (presence of only N-PCs with < 10−4 MM-PC sensitivity limit).